Cargando…

A surrogate-based approach for post-genomic partner identification

BACKGROUND: Modern drug discovery is concerned with identification and validation of novel protein targets from among the 30,000 genes or more postulated to be present in the human genome. While protein-protein interactions may be central to many disease indications, it has been difficult to identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillutla, Renuka C, Hsiao, Ku-chuan, Brissette, Renee, Eder, Paul S, Giordano, Tony, Fletcher, Paul W, Lennick, Michael, Blume, Arthur J, Goldstein, Neil I
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57814/
https://www.ncbi.nlm.nih.gov/pubmed/11602024
http://dx.doi.org/10.1186/1472-6750-1-6
_version_ 1782120055120592896
author Pillutla, Renuka C
Hsiao, Ku-chuan
Brissette, Renee
Eder, Paul S
Giordano, Tony
Fletcher, Paul W
Lennick, Michael
Blume, Arthur J
Goldstein, Neil I
author_facet Pillutla, Renuka C
Hsiao, Ku-chuan
Brissette, Renee
Eder, Paul S
Giordano, Tony
Fletcher, Paul W
Lennick, Michael
Blume, Arthur J
Goldstein, Neil I
author_sort Pillutla, Renuka C
collection PubMed
description BACKGROUND: Modern drug discovery is concerned with identification and validation of novel protein targets from among the 30,000 genes or more postulated to be present in the human genome. While protein-protein interactions may be central to many disease indications, it has been difficult to identify new chemical entities capable of regulating these interactions as either agonists or antagonists. RESULTS: In this paper, we show that peptide complements (or surrogates) derived from highly diverse random phage display libraries can be used for the identification of the expected natural biological partners for protein and non-protein targets. Our examples include surrogates isolated against both an extracellular secreted protein (TNFβ) and intracellular disease related mRNAs. In each case, surrogates binding to these targets were obtained and found to contain partner information embedded in their amino acid sequences. Furthermore, this information was able to identify the correct biological partners from large human genome databases by rapid and integrated computer based searches. CONCLUSIONS: Modified versions of these surrogates should provide agents capable of modifying the activity of these targets and enable one to study their involvement in specific biological processes as a means of target validation for downstream drug discovery.
format Text
id pubmed-57814
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-578142001-10-15 A surrogate-based approach for post-genomic partner identification Pillutla, Renuka C Hsiao, Ku-chuan Brissette, Renee Eder, Paul S Giordano, Tony Fletcher, Paul W Lennick, Michael Blume, Arthur J Goldstein, Neil I BMC Biotechnol Research Article BACKGROUND: Modern drug discovery is concerned with identification and validation of novel protein targets from among the 30,000 genes or more postulated to be present in the human genome. While protein-protein interactions may be central to many disease indications, it has been difficult to identify new chemical entities capable of regulating these interactions as either agonists or antagonists. RESULTS: In this paper, we show that peptide complements (or surrogates) derived from highly diverse random phage display libraries can be used for the identification of the expected natural biological partners for protein and non-protein targets. Our examples include surrogates isolated against both an extracellular secreted protein (TNFβ) and intracellular disease related mRNAs. In each case, surrogates binding to these targets were obtained and found to contain partner information embedded in their amino acid sequences. Furthermore, this information was able to identify the correct biological partners from large human genome databases by rapid and integrated computer based searches. CONCLUSIONS: Modified versions of these surrogates should provide agents capable of modifying the activity of these targets and enable one to study their involvement in specific biological processes as a means of target validation for downstream drug discovery. BioMed Central 2001-09-25 /pmc/articles/PMC57814/ /pubmed/11602024 http://dx.doi.org/10.1186/1472-6750-1-6 Text en Copyright © 2001 Pillutla et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Pillutla, Renuka C
Hsiao, Ku-chuan
Brissette, Renee
Eder, Paul S
Giordano, Tony
Fletcher, Paul W
Lennick, Michael
Blume, Arthur J
Goldstein, Neil I
A surrogate-based approach for post-genomic partner identification
title A surrogate-based approach for post-genomic partner identification
title_full A surrogate-based approach for post-genomic partner identification
title_fullStr A surrogate-based approach for post-genomic partner identification
title_full_unstemmed A surrogate-based approach for post-genomic partner identification
title_short A surrogate-based approach for post-genomic partner identification
title_sort surrogate-based approach for post-genomic partner identification
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57814/
https://www.ncbi.nlm.nih.gov/pubmed/11602024
http://dx.doi.org/10.1186/1472-6750-1-6
work_keys_str_mv AT pillutlarenukac asurrogatebasedapproachforpostgenomicpartneridentification
AT hsiaokuchuan asurrogatebasedapproachforpostgenomicpartneridentification
AT brissetterenee asurrogatebasedapproachforpostgenomicpartneridentification
AT ederpauls asurrogatebasedapproachforpostgenomicpartneridentification
AT giordanotony asurrogatebasedapproachforpostgenomicpartneridentification
AT fletcherpaulw asurrogatebasedapproachforpostgenomicpartneridentification
AT lennickmichael asurrogatebasedapproachforpostgenomicpartneridentification
AT blumearthurj asurrogatebasedapproachforpostgenomicpartneridentification
AT goldsteinneili asurrogatebasedapproachforpostgenomicpartneridentification
AT pillutlarenukac surrogatebasedapproachforpostgenomicpartneridentification
AT hsiaokuchuan surrogatebasedapproachforpostgenomicpartneridentification
AT brissetterenee surrogatebasedapproachforpostgenomicpartneridentification
AT ederpauls surrogatebasedapproachforpostgenomicpartneridentification
AT giordanotony surrogatebasedapproachforpostgenomicpartneridentification
AT fletcherpaulw surrogatebasedapproachforpostgenomicpartneridentification
AT lennickmichael surrogatebasedapproachforpostgenomicpartneridentification
AT blumearthurj surrogatebasedapproachforpostgenomicpartneridentification
AT goldsteinneili surrogatebasedapproachforpostgenomicpartneridentification